Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-08-26

FDA Approved: NORTREL 7/7/7 (28 DAY REGIMEN) — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Nortrel 7/7/7 (28 day regimen), updating labeling to reflect a 28-day regimen for norethindrone and ethinyl estradio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NORTREL 7/7/7 (28 DAY REGIMEN) (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for NORTREL 7/7/7 (28 DAY REGIMEN) (NORETHINDRONE AND ETHINYL ESTRADIOL)